New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Check below for free stories on BMY;PFE;DUF;CG;HLF;CALM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
April 21, 2014
09:21 EDTPFEOn The Fly: Pre-Market Movers
HIGHER: Sarepta (SRPT), up 54% after announcing plans to to submit NDA for Eteplirsen by year end 2014. Shares of Prosnesa (RNA), another drugmaker working on a competing DMD drug, are up more than 12%... AstraZeneca (AZN), up 6% after the Sunday Times says that Pfizer (PFE) is considering a takeover bid for the company. Pfizer is up 1.2% following the report... Newmont Mining (NEM), up 8% after WSJ says the company and Barrick Gold (ABX) could resume merger talks as soon as today... Cbeyond (CBEY), up 39% after agreeing to be acquired for about $323M by Birch Communications... Momenta Pharma (MNTA), up 10.5% after the Supreme Court rejected Teva's (TEVA) bid to delay generic Copaxone... Nu Skin (NUS), up 5% after saying its China division will resume corporate-hosted business meetings... Micron (MU), up 4% after price target raised at Drexel Hamilton... DOWN AFTER EARNINGS: Acacia Research (ACTG), down 6%... athenahealth (ATHN), down 5.6%.
07:47 EDTPFEPfizer unlikely to have been interested in AstraZeneca, says Bernstein
Subscribe for More Information
07:21 EDTBMY, PFEFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
07:06 EDTPFEPfizer bid for AstraZeneca 'looks highly probable,' says Citigroup
Citigroup believes Pfizer's (PFE) reported takeover interest in AstraZeneca (AZN) "looks highly probable." Citi thinks a deal would fit Pfizer's strategic goals for immunotherapy and autoimmune disease and would also be financially attractive. The firm expects Pfizer to "aggressively" approach AstraZeneca a second time.
06:47 EDTPFEAstraZeneca volatility elevated, said to have been approached by Pfizer – report
AstraZeneca (AZN) implied volatility is expected is to move on Pfizer (PFE) is said to have approached to propose a $101B takeover, says the Sunday Times. Overall option implied volatility of 20 is above its 26-week average of 18 according to Track Data, suggesting large price movement.
06:40 EDTPFEPfizer volatility flat said to be considering bid for AstraZeneca – report
Subscribe for More Information
April 20, 2014
20:37 EDTPFEPfizer said to be considering GBP60B bid for AstraZeneca, Sunday Times says
Drug giant Pfizer (PFE) is said to have approached AstraZeneca (AZN) to propose a GBP60B takeover of the U.K company, says the Sunday Times. Informal discussions have recently taken place, say sources, but AstraZeneca is believed to be resisting Pfizer’s approach, added the Sunday Times. Reference Link
16:45 EDTPFEBiogen hemophilia drug Alprolix priced similar to older treatments, Reuters says
Subscribe for More Information
April 19, 2014
11:12 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 17, 2014
15:36 EDTHLFHerbalife issues statement in response to Illinois AG investigation
Subscribe for More Information
13:50 EDTHLFIllinois AG opens investigation into Herbalife, CNBC reports
The Attorney General of Illinois has opened an investigation into Herbalife and has been in contact with the company, CNBC reports, citing sources. Shares of Herbalife dropped following the report, but remain up 30c to $55.57 in afternoon trading.
13:47 EDTHLFIllinois Attorney General investigating Herbalife, CNBC reports
Subscribe for More Information
08:38 EDTPFETeva settles patent ligitigation with Pfizer on Celebrex
Teva (TEVA) announced that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer (PFE) related to Teva’s generic version of Celebrex 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December 2014 or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Sales of Celebrex were $2.2B in the U.S. according to IMS data as of December, 2013.
07:09 EDTCGCarlyle, Bain eye Standard Chartered Hong Kong unit, Reuters says
Subscribe for More Information
April 16, 2014
11:10 EDTHLFOptions with increasing implied volatility: YOKU HLF WYNN UA
April 15, 2014
14:44 EDTHLFFederal probe of Herbalife doesn't look headed for criminal case, NYT says
Subscribe for More Information
10:17 EDTHLFHerbalife falls after NY Attorney General Schneiderman opens investigation
Shares are down over 3.7% to $51.68 after NY Attorney General Schneiderman started an investigation into claims that the company is a pyramid scheme. At current price, next support is at $51.19 and then at $49.35, both of which are recent pivot lows. Resistance is at $52.72.
08:23 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTCGJohnson & Johnson sees deal to sell K-Y brand to Reckitt closing mid-year
Sees sees deal to sell K-Y brand to Reckitt Benckiser (RBGPF) closing mid-year. Says offer from Carlyle Group (CG) to acquire Ortho-Clinical Diagnostics expected to close mid-year. Comments from slides that will be presented on the Q1 earnings conference call.
08:04 EDTPFEWuXi PharmaTech names Steve Yang as COO and Executive VP
Subscribe for More Information
07:49 EDTCGCarlyle co-CEO see more listed PE firms, focus on emerging markets, Reuters says
Subscribe for More Information
06:32 EDTBMY, PFEPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
05:55 EDTHLFHerbalife under investigation by NY AG Schneiderman, NY Post reports
Subscribe for More Information
April 14, 2014
11:54 EDTHLFStocks with call strike movement; TNA HLF
Subscribe for More Information
09:42 EDTHLFHerbalife spikes higher on low volume, levels to watch
Subscribe for More Information
09:05 EDTPFEGlycoMimetics presents GMI-1070 data
Subscribe for More Information
08:15 EDTBMYBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
05:51 EDTHLFStocks with implied volatility movement; HLF CSCO
Subscribe for More Information
April 11, 2014
16:39 EDTHLFFBI investigating Herbalife, no evidence of criminal activity, CNBC says
Subscribe for More Information
16:21 EDTHLFOn The Fly: Closing Wrap
Stocks on Wall Street were lower in a session that saw the averages struggle for direction early before sellers gained control and pushed stocks lower through the second half of the session. With today's losses, the averages each finished the week with losses greater than 2%, with the tech-heavy Nasdaq losing 3% to close below 4,000 for the first time since early February. ECONOMIC EVENTS: In the U.S., the Producer Price Index jumped 0.5% in March, versus expectations for it to be up 0.1%. The University of Michigan consumer sentiment reading jumped to 82.6 in the preliminary April look, which was better than forecast and its highest reading since July. COMPANY NEWS: JPMorgan (JPM) and Wells Fargo (WFC) kicked off earnings season for the major banks, with their quarterly results, and stocks, moving in opposite directions following the news. Dow member JPMorgan fell $2.10, or 3.66%, to $55.30 after its earnings per share and revenue significantly trailed consensus estimates. Shares of Wells gained 37c, or 0.78%, to $48.08 after the bank's profits beat the consensus forecast. MAJOR MOVERS: Among the notable gainers was BofI Holding (BOFI), up $6.02, or 8.09%, to $80.46 near midday after the company last night announced a deal to acquire H&R Block's (HRB) bank assets. H&R Block shares fell 78c, or 2.74%, to $27.64. Also higher was Zygo (ZIGO), up $4.75, or 32.36%, to $19.43 after the company agreed to be acquired by Ametek (AME) for $19.25 per share in cash in a deal that represents an aggregate enterprise value of $280M for Zygo. Among the noteworthy losers was Herbalife (HLF), down $8.36, or 13.97%, to $51.48 after a report late in the session from the Financial Times said the company is facing a criminal investigation from the U.S. Department of Justice and FBI regarding its business practices. Also lower was NQ Mobile (NQ), a recent target of noted short-seller Carson Block, down $3.29, or 20.58%, to $12.70 after its profit missed expectations and the company disclosed that it found accounting errors in its recent reports. INDEXES: The Dow was down 143.47, or 0.89%, to 16,026.75; the S&P 500 was down 17.39, or 0.95%, to 1,815.69; the Nasdaq was down 54.37, or 1.34%, to 3,999.73.
16:15 EDTHLFHerbalife says no knowledge of ongoing investigation by DoJ or FBI
Herbalife issued the following statement in response to media reports and rumors in the marketplace: "We have no knowledge of any ongoing investigation by the DoJ or the FBI, and we have not received any formal nor informal request for information from either agency. We take our public disclosure obligations very seriously. Herbalife does not intend to make any additional comments regarding this matter unless and until there are material developments."
16:07 EDTHLFHerbalife plunges on report of DOJ and FBI criminal probe
Subscribe for More Information
15:54 EDTHLFNu Skin puts active after FT reports Herbalife facing criminal investigation
Subscribe for More Information
15:47 EDTHLFHerbalife puts active on criminal probe launched, FT says
Subscribe for More Information
15:45 EDTHLFUsana, Nu Skin on lows after FT reports Herbalife facing criminal investigation
Subscribe for More Information
15:39 EDTHLFU.S. DoJ, FBI launch criminal probe into Herbalife, FT says
Subscribe for More Information
15:38 EDTHLFCriminal probe launched into Herbalife, FT says
Reference Link
15:08 EDTHLFHerbalife bracing for 20/20 report on business practices, Gasparino says
On Twitter, Charlie Gasparino said, "FBN NEWS: $HLF bracing for news magazine @ABC2020 expose on company's business practices worried abt a new whistle blower." Reference Link
07:19 EDTPFEAcura Pharma to host conference call
Subscribe for More Information
07:02 EDTCGCarlyle Group names Jeff Holland as head of private client group
Subscribe for More Information
April 10, 2014
07:04 EDTBMYBristol-Myers presents Phase III data on all-oral Daclatasvir and Asunaprevir
Subscribe for More Information
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
April 9, 2014
11:43 EDTBMYGilead defended by analysts after recent pullback
Subscribe for More Information
10:06 EDTCGOn The Fly: Analyst Upgrade Summary
AmSurg (AMSG) upgraded to Buy from Hold at Cantor... CBOE Holdings (CBOE) upgraded to Buy from Neutral at BofA/Merrill... Carlyle Group (CG) upgraded to Outperform from Perform at Oppenheimer... FireEye (FEYE) upgraded to Buy from Hold at Topeka... Fortune Brands (FBHS) upgraded to Outperform from Neutral at Credit Suisse... Gray Television (GTN) upgraded to Outperform from Market Perform at Wells Fargo... Hibbett Sports (HIBB) upgraded to Overweight from Neutral at Piper Jaffray... LinkedIn (LNKD) upgraded to Buy from Hold at Topeka... Mallinckrodt (MNK) upgraded to Buy from Neutral at UBS... NXP Semiconductors (NXPI) upgraded to Strong Buy from Outperform at Raymond James... Nexstar (NXST) upgraded to Outperform from Market Perform at Wells Fargo... Penn National (PENN) upgraded to Overweight from Equalweight at Barclays... Philip Morris (PM) upgraded to Neutral from Reduce at Nomura... SAIC (SAIC) upgraded to Market Perform from Underperform at Wells Fargo... Sinclair Broadcast (SBGI) upgraded to Outperform from Market Perform at Wells Fargo... Yelp (YELP) upgraded to Buy from Fair Value at CRT Capital... Danaher (DHR) upgraded to Strong Buy from Buy at ISI Group... Quanex (NX) upgraded at BB&T... Omnicell (OMCL) upgraded at Craig-Hallum... Volkswagen (VLKAY) upgraded to Outperform from Market Perform at Bernstein... Magna (MGA) upgraded to Neutral from Sell at Citigroup... Actavis (ACT) upgraded to Positive from Neutral at Susquehanna... E-Trade (ETFC) upgraded to Neutral from Underperform at BofA/Merrill... AmerisourceBergen (ABC) upgraded to Outperform from Market Perform at FBR Capital... CONSOL (CNX) upgraded to Outperform from Neutral at Macquarie.
07:23 EDTBMYEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:13 EDTCGCarlyle Group upgraded at Oppenheimer
As noted earlier, Oppenheimer upgraded Carlyle Group to Outperform from Perform. The firm has a positive outlook on private equity based asset managers in general, and believes that Carlyle is better positioned than most of its peers to contend with markets that could be choppy this year, given the diversification of its investments. Target $41.
06:41 EDTCGCarlyle Group upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
April 8, 2014
11:03 EDTPFE, BMYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 7, 2014
17:28 EDTPFEPfizer sell-off unwarranted, Barron's says
Subscribe for More Information
16:28 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
12:15 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTPFEPfizer trades near lows of the day, levels to watch
Subscribe for More Information
09:10 EDTPFEOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:09 EDTPFEConfusion on Pfizer Palbo could create buying opportunity, says BMO Capital
Subscribe for More Information
09:00 EDTPFEPfizer falls 2.8%
Pfizer is down 2.8%, or 90c, to $31.25
08:06 EDTBMYBristol-Myers submits NDAs for Daclatasvir and Asunaprevir to FDA
Subscribe for More Information
07:27 EDTPFEAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use